S'abonner

Epidemiology, treatment and burden of Wilson disease in France: A 10-year analysis of the national health insurance database - 24/11/22

Doi : 10.1016/j.clinre.2022.101992 
Thomas Daniel-Robin a, , Bernard Bénichou a, Claire Leboucher b, Cécile Blein b, Jean-Philippe Combal a
a Vivet Therapeutics, Paris, France 
b Creativ-Ceuticals, Lyon, France 

Corresponding author.

Highlights

1928 Wilson disease patients were found in the French health insurance database.
In the year after inclusion, 76% were hospitalised at least once for 5 days (mean).
Only 44% of patients had received a specific treatment for Wilson disease.
205 patients died during follow-up (13.5%); the mean age at death was 58 years.
67% presented at least one hepatic, neurological or psychiatric manifestation.

Le texte complet de cet article est disponible en PDF.

Abstract

Background & Aims

Wilson disease (WD) is a rare hereditary, debilitating disease that is fatal if untreated. Given its low prevalence, collecting longitudinal information on large cohorts of patients is challenging. Analysis of health insurance databases offers an approach to meet this challenge. The aim of this study was to evaluate longitudinal trends in the presentation and management of patients with WD identified in the French national health insurance database (SNDS).

Methods

This retrospective, longitudinal, observational study identified people with WD in the SNDS database through hospitalisation diagnosis codes and long-term illness status between 2009 and 2019 inclusive. For each patient, data were extracted on hospitalisations, liver transplantation, mortality, WD-specific treatments (d-penicillamine, trientine and zinc), disability status and sick leave.

Results

1,928 patients with WD were identified, of whom 1,520 (78.8%) were analysed. Prevalence of WD in 2019 was estimated as 2.2 cases per 100,000. Of the 670 patients first documented between 2010 and 2019, 76.1% were hospitalised at least once for a mean duration of 4.63±10.6 days. 152 patients (10.0%) underwent liver transplantation and 205 died (13.5%). The mean age at death was 57.9 ± 23.1 years. 665 patients (43.8%) received a WD-specific treatment at least once. 167 patients (17.1%) received a government disability pension and 624 (41.1%) benefited from long-term illness status due to WD.

Conclusions

Unexpectedly, less than half of patients with WD received treatment recommended in practice guidelines, which may contribute to a high disease burden in terms of hospitalisations, disability and reduced life expectancy. Improving treatment rates, building patient awareness of long-term disease impact or developing a new paradigm of treatment could make a significant contribution to reducing the disease burden.

Le texte complet de cet article est disponible en PDF.

Keywords : Wilson's disease, Mortality, D-penicillamine, Trientine, Zinc acetate, Sick leave, Disability, SNDS

Abbreviations : ALD, ATP7, ICD-10, IQR, MS, SD, SNDS, WD


Plan


© 2022  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 46 - N° 10

Article 101992- décembre 2022 Retour au numéro
Article précédent Article précédent
  • Is it time for global adoption of endoscopic retrograde appendicitis therapy of acute appendicitis?
  • Saif Ullah, Faisal S. Ali, Miao Shi, Ji-Yu Zhang, Bing-Rong Liu
| Article suivant Article suivant
  • Association of serum C-peptide with all-cause and cardiovascular disease mortality in ultrasound-defined nonalcoholic fatty liver disease
  • Enfa Zhao, Shimin Chen

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.